Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Amgen Astellas Seeks Japan Approval of PCSK9 Inhibitor
Amgen Astellas Biopharma K.K., a joint venture of Astellas Pharma and US-based Amgen, filed a new drug application in Japan on March 20 for evolocumab (development code: AMG145), an anti-PCSK9 monoclonal antibody for the treatment of hypercholesterolemia. Originated by Amgen,…
To read the full story
Related Article
- Amgen Astellas Building Sales Force before PCSK9 Approval
September 29, 2015
BUSINESS
- DMD Gene Therapy Elevidys Hits Japan Market at Record Price
February 20, 2026
- Bayer Eyes Kerendia as Standard Therapy for CKM Syndrome
February 20, 2026
- Enhertu Accepted for EU Review in Post-Neoadjuvant HER2 Breast Cancer
February 20, 2026
- SymBio Receives Grant for Antiviral Brincidofovir
February 20, 2026
- Over 40% of Breast Surgeons Largely Unaware of Clinical Trials: Survey
February 20, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…